CytomX Therapeutics (CTMX) Free Cash Flow (2014 - 2026)

CytomX Therapeutics' Free Cash Flow history runs 13 years deep, the most recent figure standing at -$25.5 million for Q1 2026.

• Quarterly Free Cash Flow fell 20.73% year-over-year to -$25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$80.2 million (up 1.65% YoY) and the FY2025 annual result came in at -$75.8 million, up 12.4% from the prior year.
• Free Cash Flow was -$25.5 million for Q1 2026 at CytomX Therapeutics, down from -$23.4 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $9.3 million in Q1 2023 and bottomed at -$42.0 million in Q1 2022.
• A 5-year average of -$21.0 million and a median of -$21.2 million in 2025 frame the typical range for Free Cash Flow.
• Peak annual rise in Free Cash Flow reached 122.12% in 2023, while the deepest fall reached 1262.79% in 2023.
• CytomX Therapeutics' Free Cash Flow stood at -$1.6 million in 2022, then slumped by 1262.79% to -$21.5 million in 2023, then rose by 6.88% to -$20.0 million in 2024, then declined by 17.29% to -$23.4 million in 2025, then fell by 8.98% to -$25.5 million in 2026.
• Business Quant data shows CTMX's Free Cash Flow at -$25.5 million in Q1 2026, -$23.4 million in Q4 2025, and -$15.4 million in Q3 2025.